Kliovance (Norethisterone Acetate, Estradiol)

Kliovance, containing norethisterone acetate and estradiol, is used in hormonal therapy pathways to address estrogen‑deficiency related conditions.

• Menopausal symptom relief: reduces hot flashes, night sweats, and vaginal dryness in post‑menopausal women.
• Prevention of post‑menopausal osteoporosis: supports bone mineral density maintenance in women with low estrogen levels.
• Management of menstrual irregularities: regulates endometrial shedding and treats secondary amenorrhea or dysfunctional uterine bleeding.

• Norethisterone acetate binds to progesterone receptors, exerting progestogenic effects that stabilize the endometrium, while estradiol activates estrogen receptors (ERα and ERβ) to promote gene transcription involved in bone maintenance, vasomotor regulation, and mucosal health. Together they modulate the hypothalamic‑pituitary‑gonadal axis, suppressing gonadotropin release and restoring a physiologic hormonal milieu.

Kliovance may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Breast tenderness: discomfort or swelling of breast tissue.
• Headache: transient cranial pain.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or mild depressive symptoms.
• Breakthrough bleeding: irregular spotting between periods.

Serious or Rare Side Effects

• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Severe hypertension: sudden increase in blood pressure.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Allergic reactions: rash, itching, or anaphylaxis.
• Endometrial hyperplasia: abnormal thickening of the uterine lining.

Before initiating Kliovance, clinicians should consider several safety measures.

• Cardiovascular assessment: evaluate risk factors such as hypertension, smoking, and thrombosis before initiating therapy.
• Liver function monitoring: check hepatic enzymes periodically as the drug is metabolized hepatically.
• Thromboembolic risk: advise patients to report leg pain, swelling, or sudden shortness of breath.
• Breast cancer surveillance: consider regular examinations in women with a history of hormone‑sensitive tumors.
• Smoking cessation: encourage cessation as smoking increases vascular complications.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Kliovance can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce hormonal efficacy.
• Anticoagulants (e.g., warfarin): increased risk of thrombotic or bleeding complications.
• Selective serotonin reuptake inhibitors (SSRIs): may heighten risk of serotonin syndrome when combined with certain hormonal agents.

Moderate Interactions (Monitor Closely)

• Antiepileptic drugs (e.g., carbamazepine): may alter hormone levels.
• Thyroid hormone replacement: may require dose adjustment of levothyroxine.
• Lipid‑lowering agents (e.g., statins): monitor lipid profile as hormonal therapy can affect cholesterol.